Seattle Genetics, Inc. (SGEN) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc

Cornelia Mascio
Ottobre 12, 2017

Volume is the basic fuel of the market since stocks move up or down in price only when shares are trading hands. Zacks Investment Research's price target would suggest a potential upside of 4.12% from the stock's current price. Baker Bros. Advisors Lp owns $2.64 billion in Seattle Genetics, Inc., which represents roughly 30.06% of the company's market cap and approximately 32.35% of the institutional ownership. (NASDAQ:SGEN). The Switzerland-based Swiss Retail Bank has invested 0.02% in Seattle Genetics, Inc. Investors will likely be tracking any consensus estimate changes heading into the next earnings period.

The company's quick ratio for most recent quarter is 4.00.

Other equities analysts also recently issued reports about the stock. Cann reaffirmed a "hold" rating on shares of Seattle Genetics in a report on Tuesday, August 29th. Analysts reported that the Price Target for Seattle Genetics, Inc. might touch $72 high while the Average Price Target and Low price Target is $56.38 and $43 respectively. The stock has "Hold" rating by Cantor Fitzgerald on Wednesday, August 16.

In recent trading action Seattle Genetics, Inc.

Some buy side analysts are also providing their Analysis on Seattle Genetics, Inc., where 2 analysts have rated the stock as Strong buy, 4 analysts have given a Buy signal, 9 said it's a HOLD, 1 reported it as Underperform and 0 analysts rated the stock as Sell. Seattle Genetics now has a consensus rating of "Hold" and an average price target of $61.00. Presently, Seattle Genetics Inc (SGEN) has a 14-day Commodity Channel Index (CCI) of 120.91. Icon plc had 23 analyst reports since July 29, 2015 according to SRatingsIntel. At current levels, shares have been seen trading 12.17% away from the 20-day moving average. The corporation has a market cap of US$49.55 Billion. (NASDAQ:SGEN). Nbt Fincl Bank N A Ny accumulated 18,770 shares or 0.16% of the stock. The institutional investor held 11,772 shares of the farming and seeds and milling company at the end of 2017Q2, valued at $876,000, down from 16,708 at the end of the previous reported quarter. The business's quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.23) earnings per share. Its down 0.20, from 1.5 in 2017Q1. $625,922 worth of Seattle Genetics, Inc. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and global trademark & copyright law. On Thursday, September 15 the stock rating was upgraded by Goldman Sachs to "Neutral". It worsened, as 30 investors sold SGEN shares while 75 reduced holdings. The shares were sold at an average price of $54.54, for a total transaction of $545,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The insider SIEGALL CLAY B sold 14,462 shares worth $892,897. It worsened, as 85 investors sold GE shares while 816 reduced holdings. The disclosure for this sale can be found here. Company shares were recently noted 5.88% off of the 50-day high and 37.94% away from the 50-day low. (NASDAQ:SGEN). 20,200 are owned by Tributary Mgmt Ltd Liability Company. (NASDAQ:SGEN) recently. President and CEO Clay B. Siegall let go of 18,832 shares at an average price of $53.79 on Monday the 11th.

Seattle Genetics Inc (SGEN)'s Triple Exponential Moving Average has been spotted as trending higher over the past five bars, suggesting that momentum is building for the shares. Meeder Asset Management Inc. now owns 3,950 shares of the biotechnology company's stock worth $205,000 after purchasing an additional 3,715 shares during the period. (NASDAQ:SGEN). Stifel has invested 0% in Seattle Genetics, Inc. After this sale, 77,230 common shares of SGEN are directly owned by the insider, with total stake valued at $4,747,328. Georgia-based Emory University has invested 1.08% in Seattle Genetics, Inc. The stock grabbed 44 new institutional investments totaling 2,334,942 shares while 34 institutional investors sold out their entire positions totaling 1,374,022 shares. Finally, DRW Securities LLC bought a new position in Seattle Genetics during the second quarter worth about $207,000. The Virginia-based Akre Capital Management Llc has invested 11.27% in the stock.

Institutional investors now hold around $8.16 billion or 99.2% in SGEN stock. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE